- Palabras clave > domestic production - essential medicines
- Palabras clave > essential drugs programme
- Palabras clave > funding mechanisms
- Palabras clave > local pharmaceutical industry
- Palabras clave > local production capacity
- Palabras clave > National drug programme
- Palabras clave > pharmaceutical companies - cooperation
- Palabras clave > pharmaceutical industry partnership
- Palabras clave > pharmaceutical industry social responsibility
- Palabras clave > mecanismos de financiación
(1989; 1 page)
Argentina has created a new General Agreement for the Development of the Pharmaceutical Industry that uses sales tax to fund an essential drugs programme. Companies that follow the Agreement must contribute 3% of their domestic sales, which will be used to supply essential drugs to the poor. Additionally, they must reinvest at least 3% of revenue into research and development. The Agreement also made new procedures for fast-track product registration, limited the number of approvals per company, and standardized procedures for granting pharmaceutical price increases. Multinational companies opposed the new scheme, but the national pharmaceutical industry association CILFA and the Cooperla cooperative both voiced support for it. They claimed the Agreement would lead to the growth of the national industry, import substitution, new jobs and a better balance of trade.
Abstract written by M. Tobin, 2013.